Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Health

Results: 49-60 of 7291

Business Wire logo

ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Business Wire logo

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

PR Newswire associated0

Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025

Business Wire logo

Perspectum and InHealth Announce National Diagnostics Partnership to Boost Oxford CDC Capacity and Widen Access to Advanced MRI Across the UK

PR Newswire associated0

Ziwig Endotest®: Scientific Validation Published in NEJM Evidence

Heating, injury and health greatest winter concerns for UK families with older loved ones, Elder data reveals

GMA with MOVIVA®

GMA with MOVIVA®: setting new standards in endoscopic bariatric treatment

Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

PR Newswire associated0

Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health

Business Wire logo

Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval

ACCESS Newswire associated0

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases

  • Prev Page
  • 1
  • 2
  • …
  • 4
  • 5
  • 6
  • …
  • 607
  • 608
  • Next Page

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us